(140 days)
FORA ADVANCED GD40 Blood Glucose and ß-Ketone Monitoring System is intended for the quantitative measurement of glucose in fresh capillary whole blood from the finger, and for the quantitative measurement of ß-ketone (beta-hydroxybutyrate) in fresh capillary whole blood from the finger. The FORA ADVANCED GD40 is intended for in vitro diagnostic use and is intended for single-patient use as an aid to monitor the effectiveness of a diabetes control program. The system should not be used for the diagnosis of or screening for diabetes, nor for use on neonates.
FORA ADVANCED GD40 Blood Glucose Test Strips are for use with the FORA ADVANCED GD40 Blood Glucose and ß-Ketone Meter to quantitatively measure glucose in fresh capillary whole blood samples drawn from the finger. The FORA ADVANCED GD40 Blood ß-Ketone Test Strips are for use with the FORA ADVANCED GD40 Blood Glucose and ß-Ketone Meter to quantitatively measure ß-ketone in fresh capillary whole blood samples drawn from the finger.
ß-Ketone Control Solutions are intended for use with FORA ADVANCED GD40 Blood Glucose and ß-Ketone Monitoring System to check that the meters and test strips are working together properly and that the test is performing correctly.
FORA ADVANCED GD40 pro Blood Glucose and ß-Ketone Monitoring System is intended for the quantitative measurement of glucose in fresh capillary whole blood from the finger, and from venous, and neonatal capillary heelstick whole blood, and for the quantitative measurement of ß-ketone (beta-hydroxybutyrate) in fresh capillary whole blood from the finger, and from venous whole blood. The FORA ADVANCED GD40 pro is intended for in vitro diagnostic use and is intended for multiple-patient use in professional healthcare settings as an aid to monitor the effectiveness of a diabetes control program. This system should only be used with single-use, auto-disabling lancing devices. The system should not be used for the diagnosis of or screening for diabetes.
FORA ADVANCED GD40 pro Blood Glucose Test Strips are for use with the FORA ADVANCED GD40 pro Blood Glucose and ß-Ketone Meter to quantitatively measure glucose in fresh capillary whole blood samples drawn from the fingertips, and from venous and neonatal whole blood. The FORA ADVANCED GD40 pro Blood β-Ketone Test Strips are for use with the FORA ADVANCED GD40 pro Blood Glucose and p-Ketone Meter to quantitatively measure fketone in fresh capillary whole blood samples drawn from the fingertips and from venous whole blood.
ß-Ketone Control Solutions are intended for use with FORA ADVANCED GD40 Pro Blood Glucose and ß-Ketone Monitoring System to check that the meters and test strips are working together properly and that the test is performing correctly.
The FORA ADVANCED GD40/GD40 Pro Blood Glucose and ß-Ketone Monitoring System consists of: FORA ADVANCED GD40/GD40 Pro Blood Glucose and ß-Ketone Meter (same as meter cleared under K101509, with addition of ketone testing capability), FORA ADVANCED GD40/GD40 Pro Glucose Test Strips, FORA Glucose Control Solutions (cleared under K093724), FORA ADVANCED GD40/GD40 Pro β-Ketone Test Strips, and ß-Ketone Control Solutions.
The provided document describes the FORA ADVANCED GD40/GD40 Pro Blood Glucose and ß-Ketone Monitoring System. The performance studies for both glucose and ß-ketone measurements are discussed, but specific details regarding the study design, sample sizes, ground truth establishment, or expert involvement are limited.
Here's the information extracted from the document:
1. Table of Acceptance Criteria and Reported Device Performance
| Device Performance Metric | FORA ADVANCED GD40/GD40 Pro Blood Glucose System | FORA ADVANCED GD40/GD40 Pro ß-Ketone System |
|---|---|---|
| Glucose Measurement Accuracy | System Accuracy, ISO 15197:2013 | |
| Within ±15 mg/dL of YSI for glucose concentrations < 100 mg/dL | 100% (n=100) | N/A |
| Within ±15% of YSI for glucose concentrations ≥ 100 mg/dL | 99.4% (n=490) | N/A |
| Ketone Measurement Accuracy | N/A | System Accuracy |
| Within ±0.1 mMol/L of reference for ß-ketone concentrations < 0.6 mMol/L | N/A | 100% (Single-patient use, n=50) |
| Within ±20% of reference for ß-ketone concentrations ≥ 0.6 mMol/L | N/A | 100% (Single-patient use, n=100) |
| 100% (Multi-patient use, n=190) | ||
| Precision (Repeatability) | Glucose | ß-Ketone |
| Levels (mg/dL) | SD (mg/dL) | CV (%) |
| 30-50 | 1.6 | 4.6 |
| 100-150 | 2.8 | 2.3 |
| 280-350 | 4.9 | 1.5 |
2. Sample sizes for the test set and data provenance:
- Glucose Measurement:
- For glucose concentrations < 100 mg/dL: n=100
- For glucose concentrations ≥ 100 mg/dL: n=490
- Data Provenance: "clinical settings by healthcare professionals and lay users," implying prospective clinical data. The country of origin is not specified but the company is Taiwanese.
- ß-Ketone Measurement (Single-patient use):
- For ß-ketone concentrations < 0.6 mMol/L: n=50
- For ß-ketone concentrations ≥ 0.6 mMol/L: n=100
- Data Provenance: "clinical settings by healthcare professionals and lay users," implying prospective clinical data. The country of origin is not specified but the company is Taiwanese.
- ß-Ketone Measurement (Multi-patient use):
- For ß-ketone concentrations ≥ 0.6 mMol/L: n=190
- Data Provenance: "clinical settings by healthcare professionals and lay users," implying prospective clinical data. The country of origin is not specified but the company is Taiwanese.
3. Number of experts used to establish the ground truth for the test set and their qualifications:
The document does not explicitly state the number of experts or their qualifications for establishing ground truth. The ground truth refers to a "reference" method, specifically "YSI" for glucose (likely Yellow Springs Instruments, a common lab reference method) and an unspecified "reference" for ß-ketone. Since these are in vitro diagnostic devices, the ground truth would typically be established by laboratory reference methods rather than expert clinician consensus.
4. Adjudication method for the test set:
Not applicable. The ground truth is established by laboratory reference methods, not expert adjudication.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, and its effect size:
No MRMC comparative effectiveness study is mentioned. The studies focus on the accuracy and precision of the device itself against a reference standard.
6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:
These are in vitro diagnostic devices, not AI algorithms in the traditional sense of image analysis or complex decision support. The performance reported is the standalone performance of the device and test strips in measuring glucose and ß-ketone concentrations in blood samples.
7. The type of ground truth used:
- Glucose: YSI (Yellow Springs Instruments), a laboratory reference method.
- ß-Ketone: An unspecified "reference" method.
8. The sample size for the training set:
The document does not provide information about a separate "training set" or its sample size. For in vitro diagnostic devices, the development process generally involves analytical and clinical validation, but not typically a distinct "training set" in the machine learning sense.
9. How the ground truth for the training set was established:
Not applicable, as a distinct training set (in the machine learning sense) and its ground truth establishment are not mentioned for these in vitro diagnostic devices.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized image of an eagle with three human profiles incorporated into its design. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle.
November 10, 2016
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
TAIDOC TECHNOLOGY CORPORATION PAUL LIU SENIOR REGULATORY AFFAIRS SPECIALIST 6F, NO.127, WUGONG 2ND RD., WUGU DISTRICT NEW TAIPEI CITY 24888, TAIWAN
Re: K161738
Trade/Device Name: FORA ADVANCED GD40 Blood Glucose and ß-Ketone Monitoring System
FORA ADVANCED GH40 pro Blood Glucose and ß-Ketone Monitoring System
Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose test system Regulatory Class: II Product Code: NBW, LFR, JIN, JJX Dated: September 26, 2016 Received: October 3, 2016
Dear Paul Liu:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the
{1}------------------------------------------------
electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Katherine Serrano -S
For :
Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known)
Device Name
FORA ADVANCED GD40 Blood Glucose and ß-Ketone Monitoring System
Indications for Use (Describe)
FORA ADVANCED GD40 Blood Glucose and p-Ketone Monitoring System is intended for the quantitative measurement of glucose in fresh capillary whole blood from the finger, and for the quantitative measurement of [0-ketone (beta-hydroxybutyrate) in fresh capillary whole blood from the finger. The FORA ADVANCED GD40 is intended for in vitro diagnostic use and is intended for single-patient use as an aid to monitor the effectiveness of a diabetes control program. The system should not be used for the diagnosis of or screening for diabetes, nor for use on neonates.
FORA ADVANCED GD40 Blood Glucose Test Strips are for use with the FORA ADVANCED GD40 Blood Glucose and ß-Ketone Meter to quantitatively measure glucose in fresh capillary whole blood samples drawn from the finger. The FORA ADVANCED GD40 Blood 8-Ketone Test Strips are for use with the FORA ADVANCED GD40 Blood Glucose and 0-Ketone Meter to quantitatively measure 0-ketone in fresh capillary whole blood samples drawn from the finger.
ß-Ketone Control Solutions are intended for use with FORA ADVANCED GD40 Blood Glucose and ß-Ketone Monitoring System to check that the meters and test strips are working together properly and that the test is performing correctly.
Type of Use (Select one or both, as applicable)
_ Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
{3}------------------------------------------------
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{4}------------------------------------------------
Indications for Use
510(k) Number (if known)
Device Name
FORA ADVANCED GD40 pro Blood Glucose and ß-Ketone Monitoring System
Indications for Use (Describe)
FORA ADVANCED GD40 pro Blood Glucose and ß-Ketone Monitoring System is intended for the quantitative measurement of glucose in fresh capillary whole blood from the finger, and neonatal capillary heelstick whole blood, and for the quantitative measurement of [3-ketone (beta-hydroxybutyrate) in fresh capillary whole blood from the finger, and from venous whole blood. The FORA ADVANCED GD40 pro is intended for in vitro diagnostic use and is intended for multiple-patient use in professional healthcare settings as an aid to monitor the effectiveness of a diabetes control program. This system should only be used with single-use, auto-disabling lancing devices. The system should not be used for the diagnosis of or screening for diabetes.
FORA ADVANCED GD40 pro Blood Glucose Test Strips are for use with the FORA ADVANCED GD40 pro Blood Glucose and ß-Ketone Meter to quantitatively measure glucose in fresh capillary whole blood samples drawn from the fingertips, and from venous and neonatal whole blood. The FORA ADVANCED GD40 pro Blood β-Ketone Test Strips are for use with the FORA ADVANCED GD40 pro Blood Glucose and p-Ketone Meter to quantitatively measure fketone in fresh capillary whole blood samples drawn from the fingertips and from venous whole blood.
ß-Ketone Control Solutions are intended for use with FORA ADVANCED GD40 Blood Glucose and ß-Ketone Monitoring System to check that the meters and test strips are working together properly and that the test is performing correctly.
Type of Use (Select one or both, as applicable)
2 Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
{5}------------------------------------------------
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{6}------------------------------------------------
Image /page/6/Picture/0 description: The image shows the logo for TaiDoc, a company that specializes in medical devices. The logo features the company name in gray, with three red hearts underneath. Below the hearts is the company's website address, www.taidoc.com, in white text on a gray background.
510(k) Summary
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR 807.92.
The Assigned 510(k) number is:
1. Submitter Information
| Company Name: | TaiDoc Technology Corporation |
|---|---|
| Contact Person: | Paul Liu |
| Title: | Regulatory Affairs Specialist |
| Address: | B1-7F, No. 127, Wugong 2nd Rd., Wugu District, New Taipei City, 24888, Taiwan |
| Phone: | +886-2-6625-8188 |
| Fax: | +886-2-6625-0288 |
| E-mail: | paul@taidoc.com.tw |
| Prepared Date: | June 19th, 2016 |
2. Regulatory information:
| Proprietary Name: | FORA ADVANCED GD40 Blood Glucose and β-KetoneMonitoring SystemFORA ADVANCED GD40 pro Blood Glucose and β-KetoneMonitoring Systemβ-Ketone Control Solution |
|---|---|
| Common Name: | Blood Glucose and β-Ketone Monitoring System |
| Product Code: | NBW - Blood Glucose Test System, Over-the-CounterLFR - Glucose DehydrogenaseJIN - nitroprusside, ketones (urinary, non-quant.)JJX - single (specified) analyte controls (assayed and unassayed) |
| Classification Panel: | 75, Clinical chemistry |
| Classification: | Class II (glucose)Class I (β-Ketone) |
| Regulation Citation: | 21 CFR §862.1345. Glucose test system |
{7}------------------------------------------------
Image /page/7/Picture/0 description: The image shows the logo for TaiDoc. The logo consists of the word "TaiDoc" in gray, followed by three red hearts in a row. Below the hearts is a gray rectangle with the text "www.taidoc.com" in white.
21 CFR 862.1435 Ketones (nonquantitative) test system 21 CFR 862.1660 Quality control material (assayed and unassayed)
3. Predicate Device
Nova Max Plus Blood Glucose and B-Ketone Monitor System (K091547)
4. Intended Use
Single-patient use
FORA ADVANCED GD40 Blood Glucose and β-Ketone Monitoring System is intended for the quantitative measurement of glucose in fresh capillary whole blood from the finger, and for the quantitative measurement of ß-ketone (beta-hydroxybutyrate) in fresh capillary whole blood from the finger. The FORA ADVANCED GD40 is intended for in vitro diagnostic use and is intended for single-patient use as an aid to monitor the effectiveness of a diabetes control program. The system should not be used for the diagnosis of or screening for diabetes, nor for use on neonates.
FORA ADVANCED GD40 Blood Glucose Test Strips are for use with the FORA ADVANCED GD40 Blood Glucose and ß-Ketone Meter to quantitatively measure glucose in fresh capillary whole blood samples drawn from the finger. The FORA ADVANCED GD40 Blood ß-Ketone Test Strips are for use with the FORA ADVANCED GD40 Blood Glucose and ß-Ketone Meter to quantitatively measure ß-ketone in fresh capillary whole blood samples drawn from the finger.
ß-Ketone Control Solutions are intended for use with FORA ADVANCED GD40 Blood Glucose and B-Ketone Monitoring System to check that the meters and test strips are working together properly and that the test is performing correctly.
{8}------------------------------------------------
Image /page/8/Picture/0 description: The image shows the logo for TaiDoc. The logo consists of the word "TaiDoc" in gray font, followed by three red hearts. Below the logo is the website address "www.taidoc.com" in white font on a gray background.
Multiple-patient use
泰博科技股份有限公司 aiDoc Technology Corp.
新北市24888石股區五工二路1 Jew Tainei City 24888 Taiwar
Fax · +886-7-6625-0288
FORA ADVANCED GD40 pro Blood Glucose and ß-Ketone Monitoring System is intended for the quantitative measurement of glucose in fresh capillary whole blood from the finger, and from venous, and neonatal capillary heelstick whole blood, and for the quantitative measurement of ß-ketone (beta-hydroxybutyrate) in fresh capillary whole blood from the finger, and from venous whole blood. The FORA ADVANCED GD40 pro is intended for in vitro diagnostic use and is intended for multiple-patient use in professional healthcare settings as an aid to monitor the effectiveness of a diabetes control program. This system should only be used with single-use, auto-disabling lancing devices. The system should not be used for the diagnosis of or screening for diabetes.
FORA ADVANCED GD40 pro Blood Glucose Test Strips are for use with the FORA ADVANCED GD40 pro Blood Glucose and ß-Ketone Meter to quantitatively measure glucose in fresh capillary whole blood samples drawn from the fingertips, and from venous and neonatal whole blood. The FORA ADVANCED GD40 pro Blood ß-Ketone Test Strips are for use with the FORA ADVANCED GD40 pro Blood Glucose and ß-Ketone Meter to quantitatively measure ß-ketone in fresh capillary whole blood samples drawn from the fingertips and from venous whole blood.
ß-Ketone Control Solutions are intended for use with FORA ADVANCED GD40 Pro Blood Glucose and ß-Ketone Monitoring System to check that the meters and test strips are working together properly and that the test is performing correctly.
5. Device Description:
The FORA ADVANCED GD40/GD40 Pro Blood Glucose and ß-Ketone Monitoring System consists of: FORA ADVANCED GD40/GD40 Pro Blood Glucose and ß-Ketone Meter (same as meter cleared under K101509, with addition of ketone testing capability), FORA ADVANCED GD40/GD40 Pro Glucose Test Strips, FORA Glucose Control Solutions (cleared under K093724), FORA ADVANCED GD40/GD40 Pro β-Ketone Test Strips, and ß-Ketone Control Solutions.
{9}------------------------------------------------
Image /page/9/Picture/0 description: The image shows the TaiDoc logo. The logo consists of the word "TaiDoc" in gray, with three red hearts below it. Below the hearts is the website address "www.taidoc.com" in white text on a gray background. The logo is simple and clean, with the hearts adding a touch of warmth.
6. Comparison to the Predicate:
The FORA ADVANCED GD40/GD40 Pro Blood Glucose and ß-Ketone Monitoring System uses the same fundamental technology and has same intended use as the predicate device Nova Max Plus Blood Glucose and B-Ketone Monitor System (K091547).
Test Principle : 7.
Glucose measurement is based on electrochemical biosensor technology using the enzyme Glucose Dehydrogenase to catalyze the formation of gluconolactone from the oxidation of glucose whereby two electrons are produced. The electrical current resulting from this enzymatic reaction is measured and correlated to glucose concentration by the meter. The magnitude of the current is proportional to the concentration of glucose in the sample. The test strip is calibrated to display the equivalent of plasma glucose values to allow comparison of results with laboratory methods. Using the same technology, B-hydroxybutyrate (B-ketone) is converted by B-hydroxybutyrate dehydrogenase and the magnitude of electrical current resulting from this enzymatic reaction is proportional to the amount of ß-hydroxybutyrate present in the sample.
The ß-ketone control solution contain known amount of ß-hydroxybutyrate that reacts with ß-ketone test strip intended for use as quality checks.
8. Performance Studies:
The performance of the FORA ADVANCED GD40/GD40 Pro Blood Glucose and ß-Ketone Monitoring System was studied in the laboratory and clinical settings by healthcare professionals and lay users. The studies demonstrate that the intended users can obtained blood Glucose and ß-Ketone results that are substantially equivalent to the current methods for blood glucose and ß-Ketone measurement.
9. Conclusion:
Based on the results of laboratory and clinical studies provided in this submission, FORA ADVANCED GD40/GD40 Pro Blood Glucose and ß-Ketone Monitoring System is substantially equivalent to the predicate devices.
§ 862.1345 Glucose test system.
(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.